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Background: Altered hypothalamo-pituitary-adrenal (HPA) axis activity may be accompanied by a modulation of pain
sensitivity. In a model of neuropathic pain (chronic constriction injury, CCI) we investigated the onset and maintenance
of mechanical allodynia/hyperalgesia and the expression of biochemical mediators potentially involved in spinal cell
modulation in two rat strains displaying either hypo- (Lewis-LEW) or hyper- (Fischer 344-FIS) reactivity of the HPA axis.
Results: Mechanical pain thresholds and plasmatic corticosterone levels were assessed before and during periods of
4 or 21 days following CCI surgery. At the end of the respective protocols, the mRNA expression of glial cell markers
(GFAP and Iba1) and glutamate transporters (EAAT3 and EAAT2) were examined. We observed a correlation between
the HPA axis reactivity and the pain behavior but not as commonly described in the literature; LEW rats seemed to be
less sensitive than FIS from 4 to 14 days after the CCI surgery when looking at the mechanical allodynia/hyperalgesia.
However, the biochemical spinal markers expression we observed is conflicting.
Conclusion: We did not find a specific causal relation between the pain behavior and the glial cell activation or the
expression of the glutamate transporters, suggesting that the interaction between the HPA axis and the spinal
activation pattern is more complex in a context of neuropathic pain.
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Neuropathic pain is the consequence of a lesion or a dis-
ease affecting the central and/or the peripheral nervous
system [1]. It is a major and common health issue
remaining difficult to treat [2].
Clinical studies have shown that many patients suffering
from functional pain syndromes like fibromyalgia [3], mi-
graine and tension headache [4], trigeminal neuralgia [5],
low-back pain [6] or rheumatic arthritis [7] display a re-
duced hypothalamic-pituitary-adrenal (HPA) axis reactiv-
ity. The HPA axis is an interface between the endocrine
and the nervous system and plays an important role in the
maintenance of homeostasis during stressful events [8].
It has been hypothesized that an alteration of adrenocor-
tical reactivity may lead to an ongoing sensitization of* Correspondence: ulrike.hanesch@uni.lu
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unless otherwise stated.peripheral or central nociceptive neurons [9] and hence to
the enhanced pain sensitivity observed in these patients.
Many studies attempted to elucidate the relationship
between altered HPA axis activity and nociception
through different animal models. Lewis (LEW) and Fischer
344 (FIS) are two histocompatible inbred rat strains pre-
senting different HPA axis reactivity. Relative to other
strains, LEW rats exhibit a blunted HPA axis activity due
to a reduced synthesis and secretion of corticotropin-
releasing hormone (CRH), leading to a decreased release
of adrenocorticotropic hormone (ACTH) from the pituit-
ary and corticosterone from the adrenal cortex [10-13].
On the contrary, the HPA axis of FIS rats is hyperres-
ponsive, resulting in a significantly higher blood cor-
ticosterone level compared to LEW rats [10]. Basal and
stimulated pro-inflammatory cytokine levels also have
been shown to be increased in LEW relative to FIS [14].
The two strains display sensitivity discrepancies in re-
sponse to acute and chronic pain, including neuropathic
pain [15-17]. As shown by Fecho and Valtschanoff [16]Ltd. This is an Open Access article distributed under the terms of the Creative
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correlate with their exacerbated mechanical allodynia
exhibited after partial sciatic nerve ligation. However, the
development and maintenance of neuropathic pain re-
quire a complex network of pathways [18], implying that
differences in HPA axis cannot per se explain the observed
strain-specific differences in neuropathic pain behavior.
The glutamatergic system is known to be part of this
pain-controlling network. Glutamate is a major ex-
citatory neurotransmitter whose actions are mediated by
ionotropic and metabotropic receptors [18], and is
considered as the main pain mediator [19]. After injury,
glutamate-induced plasticity plays a key role in the
mechanism of activity-dependent central sensitization,
thus contributing to the development of post-injury pain
hypersensitivity [20]. The role of glutamate in nocicep-
tion is also dependent on its transporters, the excitatory
amino acid transporters (EAATs), which control gluta-
mate clearance and its availability [21-25]. Actually, it
has been shown in a chronic constriction injury (CCI)
model of neuropathic pain that spinal glucocorticoid re-
ceptor activation mediates a downregulation of EAAC1/
EAAT3 expression, a neuronal transporter of glutamate,
in the spinal cord dorsal horn [26]. As a result, the
glutamatergic activity and glutamate-mediated neuronal
plasticity would be enhanced and could contribute to
the neuropathic pain behavior.
Microglial and astrocytic activation is also involved in
the initiation and maintenance of neuropathic pain
[27-33]. This activation leads to an increased expression
of specific microglial and astrocytic markers such as Iba-1
and GFAP, respectively [34,35] and enhances pain sensi-
tivity via the release of pro-inflammatory cytokines and
glutamate [36-41].
In light of these studies, genesis and maintenance of
neuropathic pain imply the supraspinal and spinal parts of
the central nervous system, along with their neuronal
and non-neuronal components. In the present study, we
focused on the regulation of these different systems at the
spinal level in three rat strains displaying different HPA
axis reactivity backgrounds. More specifically, we assessed
the mechanical allodynia of LEW, FIS and Wistar (WIS)
rats undergoing CCI-induced neuropathic pain and
measured their plasma corticosterone levels over time.
Additionally, we quantified the expression of glutamate
transporters (EAAT2 and EAAT3) and astrocytic/micro-
glial activation markers (GFAP and Iba-1, respectively) in
the spinal cord of each of the respective rat strains.
Methods
Animals
Experiments were performed in 108 adult 50-60 day old
male LEW, FIS, and WIS rats (36 animals per strain)
weighing 124-184 g. The study was only performed inmale rats to avoid potential interactions with estrogens.
The animals (Harlan Laboratories, Netherlands) were
housed three per cage in a temperature-controlled room
(20-22°C) under a 12 h day-night cycle. Food and water
were provided ad libitum. Starting two weeks before initi-
ation of the experiments the animals were handled daily
and habituated to the behavioral testing room and devices.
The Animal Care and Use Committee of the University of
Luxembourg approved all animal procedures.
CCI and sham surgery
For CCI surgery, the rats were anesthetized with isoflu-
rane (Isoflo®, Abbott Laboratories Ltd, Berkshire, UK)
using an anesthesia unit (Univentor 400, Zejtun, Malta).
The right sciatic nerve was exposed and three loose
Dexon S (United States Surgical, Tyco Healthcare Group,
North Haven, CT, USA) ligatures were placed around the
nerve in a distance of about 1 mm. Subsequently, the
muscle layer was stitched with 4–0 silk suture and the
skin layer was closed with surgical skin staples.
For the sham operation, rats underwent the same sur-
gical procedure but without placing ligatures around the
sciatic nerve. These animals were used as controls since
our goal was to characterize parameters specifically re-
lated to the development and maintenance of neuro-
pathic pain that should be differentiated from effects
induced by the surgical procedure per se. We took into
account that the respective (control) pain behavior and
biochemical processing might also change over the test
period by plotting differences for identical time points.
Experimental protocol
The 36 animals per strain were grouped as follows: 24 rats
(12 that received sham operation and 12 that underwent
CCI surgery) were taken for behavioral tests and blood
sampling. They were sacrificed at the end of the experi-
ment at day 21. Half of the rats (6 sham and 6 CCI per
strain) were perfused for further immunohistochemical
procedures and the other half (also 6 sham and 6 CCI per
strain) were decapitated for mRNA isolation and subse-
quent qPCR performing. The remaining 12 rats per strain
(6 sham and 6 CCI operated) were sacrificed already 4 days
after the surgery for isolation of mRNA and subsequent
qPCR.
We chose day 4 as the first time point of measurement
of biochemical markers since by then acute neuropathy
had developed while effects primarily related to surgery
should have declined. In addition, the FIS and LEW rats
displayed differential levels of pain behavior at that time
point. In order to obtain measurements relative to the
maintenance of neuropathy, a second set of biochemical
data was collected at day 21 when the tested strains still
displayed pronounced levels of CCI-related mechanical
allodynia.
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tive days preceding the operation (days −2, −1 and 0) to
reveal baseline values. After the CCI or sham surgery (day
0) further measurements were performed on days 4, 7, 10,
14, and 21.
Blood sampling was carried out on day 0 to reveal
baseline corticosterone levels and on days 1, 4, 7, 14,
and 21 following CCI surgery.
Von Frey monofilament test
The von Frey test (OptiHair, MarstockNervTest, Germany)
was used to measure mechanical allodynia/hyperalgesia.
Rats were placed in Plexiglas® cages with a wire mesh floor
and given 10 min to acclimate. Each monofilament was
placed perpendicularly onto the midplantar surface of the
hind paw and pressure was increased until the point of de-
flection of the filament was reached. Pain thresholds were
determined by the ascending and descending method of
limits with forces ranging from 8 to 256 mN in 11 loga-
rithmic steps [42]. Each test was repeated three times and
the mean was calculated for each paw.
For each strain the baseline was calculated as mean of
days −2, −1, and 0. For a better assessment of the CCI
effect in the individual strains we set the baseline as
100% for each animal and expressed the paw withdrawal
thresholds of the right affected paw as percentage of
baseline. For each time point the mean per strain was
computed. The data are presented as mean ± standard
error of the mean (s.e.m.).
Blood sampling and measurement of corticosterone
levels
Blood sampling was performed in awake animals between
9 h00 and 9 h30, half an hour before the start of the be-
havioral tests. To minimize stress reactions, rats were
loosely held in a towel. A small incision about 15 mm
from the end of the tail was made by the use of a scalpel.
300 μl of blood was collected with a capillary tube coated
with EDTA (Microvette CB300). The samples were imme-
diately placed on ice, then centrifuged at 4°C for 10 min
and the plasma was removed and stored at −20°C. Serum
corticosterone levels were measured using an ELISA (En-
zyme-Linked Immunosorbent Assay) kit (Assay Designs,
USA). The analysis was performed according to the
manufacturer’s protocol. Data were acquired via a plate
reader (Sunrise Magellan, Austria) and an adequate soft-
ware package (Magellan software, v6.4 standard, Austria).
Tissue preparation for immunohistochemistry
At day 21, the 12 rats per strain (6 CCI and 6 sham opera-
ted animals) that were planned for protein quantification
by immunohistochemistry were deeply anesthetized with
an intraperitoneal injection of Penthotal (100 mg/kg,
Abbott Laboratories, IL, USA). Initially a solution oftyrode (pH 7.3) containing heparin (Heparin-Natrium
Braun, 10,000 I.E./ml, 2 ml/l) was perfused transcardially
followed by Zamboni’s fixative consisting of 4% paraform-
aldehyde and 0.2% picric acid in 0.1 M phosphate-
buffered saline (PBS; pH 7.4). Spinal cord segments L4
and L5 were removed and post-fixed in the same fixative
during at least 2 h. Following cryoprotection in 30%
sucrose in 0.1 M phosphate buffer (PB) at 4°C for 2 h,
30 μm sections of spinal cord were cut using a cryostat
and mounted on microscope slides (10–15 sections per
slide).
Immunohistochemistry
The spinal cord sections were washed in PBS and incu-
bated in 0.1% H2O2 to inactivate endogenous peroxidases.
Then they were rinsed in three changes of PBS and subse-
quently preincubated during 30 min in 5% normal serum
in PBS containing 0.5% Triton X-100. Afterwards, the
sections were incubated overnight at room temperature
with either anti-GFAP (1:3000, Z0334, DAKO) or anti-
Iba1 (1:1000, CP 290B, Biocare Medical) antisera diluted
in PBS containing 1% normal serum and 0.5% Triton
X-100. The primary antibodies were visualized by the
avidin-biotin-complex method (Vectastain Elite ABC Kit,
Vector Laboratories). The spinal cord sections were rinsed
in PBS (5 × 10 min), incubated in the secondary bio-
tinylated antibody for 1 h and immediately placed in AB-
complex for 30 min. After rinsing with PBS (5 × 10 min),
the peroxidase was visualized with 0.03% 3,3’-diaminoben-
zidine tetrahydrochloride (DAB, Sigma) activated with
0.01% H2O2. The reaction was stopped with distilled water
and excess reaction product was washed out with PB.
The sections were dried overnight and then dehydrated
through ascending concentrations of alcohol, followed by
three changes of xylene. Finally, the slides were cover-
slipped using DePex (Serva, Germany).
Quantitative microscopy
Five immunostained spinal cord sections per slide were
randomly selected on an AxioImager D1 microscope
(Carl Zeiss) and photographed (AxioCam MRm, Carl
Zeiss). Using a software tool (AxioVision, Carl Zeiss) a
mask representing the boundaries of the dorsal horn
(lamina I to V) was drawn for further image analysis. To
differentiate background staining from true positive im-
munostaining statistical clues were used as described by
Hoheisel et al. [43]. For each section the grey values of
three randomly chosen unstained areas were measured
and the mean was defined as background. The threshold
level for “true” immunostaining was then set as the
background value plus three standard deviations. After-
wards, the software was able to compute the ratio (in
percentage) of immunostained area to total area (=area
of the mask), also expressed as staining density.
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staining density of the left side of the spinal cord both
when comparing the three strains and the control versus
CCI conditions. This allowed us to consider the left dor-
sal horn (contralateral to CCI) as control and to set the
respective staining density as 100%. The % change for
the right dorsal horn (ipsilateral to CCI) was calculated
for each spinal level of each rat. Finally, the mean per
level per strain was calculated.
Sample collection and RNA isolation
At day 4 or 21 post surgery the 12 animals per strain
per time point (6 sham and 6 CCI each) selected for
RNA isolation were anesthetized with isoflurane and de-
capitated. Levels L4/L5 of the spinal cord were removed
and ipsi- and contra-lateral sides were separated. Total
RNA was extracted using the Invitrap Spin Tissue RNA
Microkit (Invitek, Berlin, Germany). The total RNA con-
centration was determined by measuring the absorbance
at 260 nm, using a Nanodrop ND-2000 spectrophoto-
meter (Thermo Fisher Scientific, Wilmington, USA).
Reverse transcription and real-time qPCR
Total RNA (500 ng) was reverse transcribed into cDNA
using the ImProm-II Reverse Transcription System
(Promega Corporation, Madison, USA). Real-Time PCR
reactions were performed from 10 ng of cDNA with a
CFX-96 thermocycler (Bio-Rad Laboratories, Nazareth,
Belgium). SYBR green Supermix PerfeCTa (95053-02 K,
Quanta Biosciences, Gaithersburg, MD, USA) was used
for the detection of Iba1, GFAP, EAAT2, EAAT3, and
β-actin (as internal reference). Primer sequences are
listed in Table 1. The steps consisted of one cycle of
3 min at 95°C and 40 cycles of amplification (10 sec at
95°C, 30 sec at 61°C). All samples were run in triplicate.
Relative expression was estimated using the standard
ΔΔCT-method published by Pfaffl [44]. In this mathe-
matical model threshold cycle values (CT) were used to
compute the amount of target gene mRNA in relation toTable 1 Sequences of primers used in this study
Name Accession Sequence
β-actin NM_031144 5′ GCT GAG AGG GAA ATC GTG CGT GAC 3′
5′ GGA GGA AGA GGA TGC GGC AGT GG 3′
Iba1 NM_017196 5′ TCC CAT CCA ACC TCT CTT CC 3′
5′ GCA GCC TCA TCG TCA TCT C 3′
GFAP NM_017009 5′ TGA GTC GCT GGA GGA GGA G 3′
5′ GCT GTG AGG TCT GGC TTG G 3′
EAAT3 NM_013032.3 5′ TCA TAG TCG GGA AGA AC 3′
5′ AGC GGA ATG TAA CTG GAA GG 3′
EAAT2 NM_017215 5′ ATG CTC CTC ATT CTC ACA G 3′
NM_001035233 5′ CTA CAT TGA CCG AAG TTC TC 3′the reference gene mRNA (β-actin). ΔCT represents the
difference between the number of cycles that were neces-
sary to detect the PCR products of the target and the
reference genes. The ΔΔCT indicates the difference
between the ΔCT of the neuropathic group and the ΔCT
of the sham-operated (control) animals and reflects the
extent of fold difference of under- or overexpression of
the gene of interest in the CCI animals relative to the
sham-operated control group (relative expression level of
control = 1). The data were expressed as 2-ΔΔCT. For each
strain the mean was computed.
Statistical analysis
Statistical analyses for mechanical thresholds and cor-
ticosterone levels were carried out using an analysis of
variance (ANOVA) followed by a Scheffé post hoc test to
check for differences between strains. Comparisons of
mechanical thresholds between sham and CCI groups of
each strain were performed with a student’s t-test. PCR
and immunohistochemical data were analyzed using
ANOVA followed by a Tukey-HSD post hoc test. P < 0.05
was defined as the level of statistical significance. Statis-
tical tests were performed with IBM SPSS Statistics ver-
sion 19 (IBM corporation, Somers, NY, USA).
Results
Effect of CCI surgery on mechanical pain thresholds in
LEW, FIS and WIS rats
On three consecutive days before performing CCI or
sham surgery LEW, FIS, and WIS rats were tested for
baseline mechanical paw withdrawal thresholds. The aver-
age threshold of the right hind paw was 111.83 ± 4.54 mN
for LEW, 91.85 ± 5.84 mN for FIS, and 90.72 ± 5.76 mN
for WIS rats. Statistical analysis revealed significant diffe-
rences in mechanical sensitivity between LEW and FIS
(p = 0.032) and between LEW and WIS rats (p = 0.020).
Whereas FIS and WIS did not differ in their withdrawal
latency before surgery, LEW was less sensitive. In order to
assess the effects of sciatic nerve injury on pain behavior
in the individual strains, we calculated the pain thresholds
at the different time points in relation to baseline, which
was set to 100%.
In the sham operated (control) groups mechanical pain
thresholds slightly decreased in all three strains. The paw
withdrawal latency in WIS rats descended to 84.01 ± 6.60%
of baseline 4 days after sham surgery and subsequently re-
covered at d14 (d7: 85.57 ± 5.44; d10: 90.27 ± 5.93; d14:
99.81 ± 9.95; d21: 94.49 ± 8.81). In LEW rats the mechani-
cal pain threshold decreased to 78.15 ± 6.71% of baseline
at d4 and slightly increased until d21 (d7: 79.09 ± 5.57;
d10: 88.30 ± 3.76; d14: 72.36 ± 4.18; d21: 85.51 ± 7.12).
FIS rats proved to be more sensitive to the sham operation
compared to LEW and WIS. Their paw withdrawal la-
tency dropped to 73.94 ± 5.62% of baseline on d4 and
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4.22; d10: 58.80 ± 5.64; d14: 70.22 ± 5.88; d21: 53.43 ±
4.46). Statistical analysis (ANOVA followed by Scheffé
post hoc test) revealed significant differences between the
FIS and WIS strains on days 7 to 21 (d7: p = 0.019; d10:
p = 0.0008; d14: p = 0.025; d21: p = 0.0008) and between
the FIS and LEW rats on days 10 (p = 0.002) and 21
(p = 0.009).
After CCI surgery (Figure 1) the mechanical thresholds
in LEW rats dropped to 43.12 ± 7.29% of baseline at d4
and remained at that level until the end of the experi-
ment at d21 (d7: 41.54 ± 8.17; d10: 35.12 ± 6.50; d14:
43.43 ± 7.13; d21: 46.87 ± 4.86).
FIS rats displayed a higher mechanical sensitivity at d4
after operation. The paw withdrawal latency descended to
22.63 ± 2.02% of baseline and stayed at that level until d14
(d7: 23.18 ± 2.27, d10: 21.98 ± 1.91; d14: 22.25 ± 2.4). On
d21 a slight decrease of the hypersensitivity was observed
(35.61 ± 5.71).
In WIS rats the mechanical pain threshold also
dropped on d4 following CCI to 24.50 ± 2.48% of base-
line. However, there was a slight recovery in the time
course of the experiment (d7: 36.18 ± 3.14, d10: 27.46 ±
2.62; d14: 40.86 ± 3.63; d21: 51.25 ± 7.15).
Multiple comparisons revealed that LEW rats
remained less sensitive than FIS up to 14 days after the
CCI surgery (d4: p = 0.0003; d7: p = 0.019; d10: p = 0.047;m
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Figure 1 Effect of CCI on mechanical pain thresholds in LEW,
FIS and WIS rats. The paw withdrawal response to mechanical
stimulation of the right hind paw was measured in Lewis (LEW),
Fischer (FIS) and Wistar (WIS) rats before and after CCI surgery. For
up to 14 days neuropathic pain behavior was less prominent in LEW
than in FIS rats. In comparison with the control strain (WIS), LEW was
less sensitive in the early phase after nerve injury (d4), whereas FIS
showed enhanced sensitivity later on at day 14. Data are shown as
mean ± s.e.m. Asterisks represent a significant difference between
the LEW and the FIS strain for the individual time point (*p < 0.05,
**p < 0.01, ***p < 0.001). #indicates a significant difference between
LEW or FIS and WIS (#p < 0.05, ###p < 0.001).d14: p = 0.0067) and also were less sensitive than WIS on
d4 (p = 0.00096). FIS rats showed no statistical significant
difference of threshold values compared to WIS except on
d14, where FIS still was more sensitive than the control rats
(p = 0.016).
As expected, sham groups and CCI groups differed sig-
nificantly in their mechanical pain thresholds at all time
points after the surgery, independently of the strain.
Effects of CCI on plasma corticosterone levels
Blood corticosterone levels of the three strains were mea-
sured before the surgery (day 0) and at days 1, 4, 7, 14, and
21 following CCI (Figure 2). Before the operation, the cor-
ticosterone concentration was lowest in LEW rats (170.5 ±
30.0 ng/ml) and highest in FIS (353.7 ± 88.7 ng/ml). In the
WIS strain the plasma corticosterone level was 247.3 ±
31.6 ng/ml and hence was situated between the levels seen
in FIS and LEW. However, statistical comparison between
the groups did not show significant differences due to a
high variation in the FIS strain.
During the development of neuropathy FIS rats reacted
first with an increase of the corticosterone level on d1
(412.6 ± 47.2 ng/ml). In the course of the following days
the concentration did however even decrease below base-
line level (d4: 366.8 ± 64.4, d7: 291.3 ± 40.0, d14: 261.8 ±
20.5, and d21: 258.2 ± 23.3 ng/ml). In LEW rats the plas-
ma corticosterone increased slowly, peaking at d4 and
decreased slightly until the end of the experiment on d21,
without reaching the baseline level (d1: 214.2 ± 36.5, d4:
262.5 ± 46.6, d7: 236.7 ± 59.7, d14: 232.6 ± 50.6, and d21:
209.0 ± 65.6 ng/ml). WIS rats exhibited a slight increasedays0 1 4 7 14 21
co
rti
co
st
er
on
e
 le
ve
l (n
g/m
l)
0
100
200
300
400
500
LEW
WIS
FIS
Figure 2 Time course of serum corticosterone levels in
response to CCI of the right sciatic nerve. Basal corticosterone
levels (day 0) were highest in FIS and lowest in LEW rats, however
without reaching significance levels due to a high variance in the
FIS strain. Induction of neuropathy led to an increase of the
corticosterone concentration in all three strains in the first days. The
levels subsequently decreased and ended up below baseline values
in FIS rats or above in LEW. Data are shown as mean ± s.e.m.
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Figure 3 CCI-mediated mRNA expression of the glial markers
Iba1 and GFAP in the three rat strains. The relative expression level
of (A) the microglial activation marker Iba1 and (B) the activation
marker of astrocytes GFAP was measured at the spinal cord level L4/5 of
Lewis (LEW), Fischer (FIS) and Wistar (WIS) rats on days 4 and 21 after
chronic constriction injury of the right sciatic nerve. Strains only differed
in their temporal activation profile of microglia: Lewis rats reacted
shortly after CCI with a significant increase of Iba1, whereas Fischer rats
displayed a high upregulation of this marker at a later time point. The
relative expression level indicates the fold difference of the CCI group to
the sham-operated control group (control = 1). Data are expressed as
mean ± s.e.m. *p< 0.05, **p < 0.01, ***p < 0.001.
Le Coz et al. BMC Neuroscience 2014, 15:35 Page 6 of 13
http://www.biomedcentral.com/1471-2202/15/35of the corticosterone level following CCI on d1 (321.3 ±
36.0 ng/ml) and d4 (324.8 ± 34.6 ng/ml) and came back to
baseline on d7 (239.3 ± 28.3; d14: 244.1 ± 20.9, d21: 279.0 ±
24.6 ng/ml). Within the strains we did however not
observe significant differences in the temporal pattern of
corticosterone concentrations compared to day 0 which
might be related to high variability levels.
CCI induced activation of spinal glia cells in LEW, FIS, and
WIS rats
In order to characterize the activation of spinal glia cells
following the CCI surgery we examined the expression
of mRNA and protein of the glia-specific markers Iba1
(microglia) and GFAP (astrocytes) by using qPCR and
immunohistochemical techniques.
Activation of microglia
At days 4 and 21 post surgery total mRNA was isolated
from the spinal cord and, after reverse transcription into
cDNA, qPCR was performed using a specific primer for
Iba1 (Table 1) to detect differences between strains. Four
days after CCI the Iba1 mRNA was upregulated in all
three strains (Figure 3A). Whereas the relative expression
level was twofold in FIS and WIS rats (FIS: 2.03 ± 0.56;
WIS: 1.90 ± 0.31), we measured a fourfold increase in
LEW (3.98 ± 0.20). This situation reversed in the course of
the neuropathic state: 21 days after CCI surgery the rela-
tive expression level of Iba1 decreased to 2.43 ± 0.23 in
LEW rats, but increased in WIS (3.04 ± 0.48) and even
more in FIS (7.65 ± 0.48) (Figure 3A). At d4 comparison
between groups (ANOVA followed by Tukey-HSD post
hoc test) revealed a significant increase of Iba1 mRNA ex-
pression in the LEW strain compared to FIS and WIS
(LEW vs. FIS: p = 0.007; LEW vs. WIS: p = 0.003) and at
d21 a significantly higher expression level was observed
in FIS compared to LEW and WIS rats (FIS vs. LEW:
p = 0.0002; FIS vs. WIS: p = 0.0008).
At day 21 post-operation, a CCI-related activation of
microglia was detected at the ipsilateral spinal cord dorsal
horn levels L4/L5 of all three strains. The glial cells were
intensely immunostained for Iba1 and their cellular pro-
cesses appeared shorter and thicker than those in the
contralateral dorsal horn. We observed an increase in the
staining density of the Iba1 protein in the right dorsal
horn (side of surgery) compared to the left (unaffected)
side in all three strains (Figure 4). Although the staining
density was obviously higher in LEW rats (144.7 ± 5.2%)
(Figure 5), the statistical test failed to show significant
differences for the FIS (129.7 ± 5.2%) and WIS (128.1 ±
6.4%) strain.
Taken together, LEW and FIS displayed a differential
time course of microglia reaction. In LEW rats the acti-
vation of microglia was most pronounced within the first
days after nerve constriction and subsided in the courseof persistent neuropathy. In contrast, FIS displayed a sig-
nificantly delayed CCI-related considerable raise in Iba1
mRNA expression.Activation of astrocytes
Four and 21 days after CCI surgery we harvested the spinal
cord level L4/L5 and carried out qPCR by using a specific
primer for GFAP (Table 1) to detect differences between
strains. At d4 the relative expression level of GFAP mRNA
was slightly enhanced in all three strains (LEW: 1.58 ± 0.15;
FIS: 1.39 ± 0.07; WIS: 1.32 ± 0.34) (Figure 3B). Although
the mRNA expression tended to be higher in LEW rats,
the statistical evaluation did not yield significant differ-
ences in comparison with FIS and WIS animals. At 21 days
post-operation the GFAP mRNA level decreased in LEW
Figure 4 Iba1-immunostaining in LEW, FIS and WIS rats
subjected to nerve injury. The photomicrographs show the effect
of a chronic constriction injury (CCI) of the right sciatic nerve on
microglial cell activation in the dorsal horn of the spinal cord segment
L4 on day 21 after surgery in Lewis (LEW; Top), Fischer (FIS; Middle)
and Wistar (WIS; Bottom) rats. The number and staining density of
Iba1-immunopositive microglial cells was clearly enhanced in the right
dorsal horn (side of CCI) compared to the left unaffected side in all
three strains. Differences between strains were not obvious. Scale
bars: 100 μm.
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Figure 5 Staining density of the glial markers Iba1 and GFAP at
day 21 post-CCI. The immunohistochemical staining density of
microglial (Iba1) and astrocytic (GFAP) activation markers in the dorsal
horn of the spinal cord segments L4/L5 was quantified 21 days after
induction of chronic constriction injury (CCI) in Lewis (LEW), Fischer
(FIS) and Wistar (WIS) rats. Iba1- and GFAP-immunostaining was
enhanced on the side of CCI in relation to the left unaffected side
(control = 100%) in all three strains. The staining density of the
microglial marker Iba1 seemed to be higher in LEW rats compared to
FIS and WIS but this difference did not reach significance. No
differences between strains could be found for the expression of GFAP
protein. Data are shown as mean ± s.e.m.
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significantly increased in WIS (1.93 ± 0.29; WIS vs. LEW:
p = 0.038) (Figure 3B). Again, the LEW strain seemed to
display an earlier activation of this type of glia cells. How-
ever, in contrast to microglia, astrocytes were not highly
activated in FIS rats at later stages of the nerve injury.
The immunohistochemical staining of the astrocytic
marker GFAP in the spinal cord sections revealed a
change in the morphology of these glial cells at day 21
after CCI surgery. The GFAP immunostained astroglial
cells appeared hypertrophic in the right dorsal horn of
the spinal cord. Additionally, we observed an increase in
the staining density of the GFAP protein in the right
dorsal horn (side of nerve injury) compared to the left
not affected side in all three strains (Figure 6). Statisti-
cally significant differences between the strains could
not be obtained due to high variations within the groups
(LEW: 125.0 ± 14.1; FIS: 146.3 ± 10.0; WIS: 138.4 ±
15.0%) (Figure 5).Modification of neuronal and glial glutamate transporter
mRNA expression following CCI
Glutamate transporters control the availability of gluta-
mate in the synaptic cleft and thus regulate the activation
of glutamate receptors. EAAT3 (also known as EAAC1) is
associated with neurons, whereas EAAT2 is expressed in
glia cells. Here we used qPCR to assess nerve injury-
related differences in the regulation of the neuronal and
glial glutamate transporter expression in the three rat
strains.
Expression of EAAT3
Four days after CCI surgery the neuronal glutamate trans-
porter was clearly downregulated in LEW rats (0.64 ± 0.10),
to a lesser extent in WIS (0.85 ± 0.10), but unaffected in
FIS (1.05 ± 0.06) (Figure 7A). At that time point LEW sig-
nificantly differed from the FIS strain (p = 0.031).
In the course of neuropathy the relative expression level
of the neuronal transporter only changed slightly. At day
21 LEW and WIS rats still exhibited less EAAT3 mRNA
(LEW: 0.75 ± 0.07; WIS: 0.77 ± 0.06) whereas mRNA levels
tended to increase in FIS (1.14 ± 0.12) (Figure 7A). Signifi-
cant differences were obtained between FIS and LEW rats
(p = 0.019) and between FIS and WIS (p = 0.034).
Expression of EAAT2
Shortly after the CCI operation (d4) the glial glutamate
transporter also was clearly downregulated in LEW
(0.52 ± 0.06), to a lesser extent in WIS (0.68 ± 0.09) and
only slightly in FIS (0.89 ± 0.06) animals (Figure 7B). The
Figure 6 GFAP-immunostaining in LEW, FIS and WIS rats
subjected to nerve injury. The photomicrographs show the effect
of a chronic constriction injury (CCI) of the right sciatic nerve on the
activation of astrocytes in the dorsal horn of the spinal cord segment
L4 at day 21 after surgery in Lewis (LEW; Top), Fischer (FIS; Middle)
and Wistar (WIS; Bottom) rats. The number and staining density of
GFAP-immunopositive astrocytic cells was enhanced in the right dorsal
horn (side of CCI) compared to the left unaffected side in all three
strains. Significant differences between strains were not observed.
Scale bars: 100 μm.
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tween the LEW and the FIS strain (p = 0.015). At d21
post surgery the EAAT2 mRNA expression level was still
down in the LEW group (0.66 ± 0.06), there was however
a tendency towards enhancement. In WIS rats the early
decrease turned to an increase (1.32 ± 0.14) and in FIS a
nearly threefold upregulation (2.87 ± 0.64) could be ob-
served at that late time point (Figure 7B). The differ-
ences between the FIS and the two other groups are
statistically significant (FIS vs. LEW: p = 0.004; FIS vs.
WIS: p = 0.046). Taken together, the LEW strain reacted
with an early downregulation of the neuronal as well as
the glial glutamate transporter. For both markers, a
slight tendency towards recovery was after 21 days. In
contrast, FIS rats only displayed a clear modulation of
the glial glutamate transporter mRNA expression at the
later time point. This temporal reaction pattern is remi-
niscent with the time course of glia activation observed
in the two rat strains.Discussion
In the present study, we aimed to determine whether the
differential HPA axis reactivity expressed by Lewis and
Fischer rats has an impact on pain sensitivity, glial cell
activation and on the regulation of the expression of glu-
tamate transporters in a context of neuropathy. Following
CCI surgery, we observed that LEW rats were less sensi-
tive than FIS up to 14 days post-operation while the two
strains did not display any significant difference in their
plasma corticosterone levels. Regarding glial activation
and the expression of glutamate transporters, we found
different temporal transcription patterns between LEW
and FIS rats.
Development and maintenance of mechanical allodynia
Nociceptive sensitivity tests from the fourth day post-
surgery demonstrated that CCI effectively induced me-
chanical allodynia in the three rat strains. Surprisingly,
LEW rats exhibited less pain sensitivity from days 4 to
14 after surgery, as compared to the other strains. This
result is contradictory to the findings of Fecho and
Valtschanoff [16] stating that LEW rats present an
exacerbated mechanical allodynia compared to FIS rats
after partial ligation of the sciatic nerve. This discre-
pancy may result from differences in the chosen models
of neuropathic pain and the inherent surgical proce-
dures. The paradigm used in the present study may be
accompanied by a more significant injury and concomi-
tant inflammatory insult that may in turn (at least ini-
tially) lead to a more pronounced pain sensitivity in FIS
rats [45,46]. This interpretation seems to be corro-
borated by the levels of allodynia also expressed by the
sham operated FIS rats. Other investigators did not ob-
serve any differences between LEW and FIS undergoing
neuropathic pain [47,48]. Nevertheless, in accordance
with our results, LEW rats have also been described to
be less sensitive than FIS intrinsically or shortly follow-
ing peripheral inflammation [45,46,49,50]. Altered HPA-
axis reactivity may hence in fact have an impact on pain
sensitivity.
It is well known that FIS rats display significantly
higher basal and stress-related corticosterone levels than
LEW rats [10,13,51,52]. To our knowledge, no studies
exist about the long-lasting pain-related evolution of
corticosterone levels in LEW and FIS rats. Although we
failed to observe any significant differences, FIS, LEW
and WIS seemed to display different patterns of progres-
sion for this parameter. FIS displayed a lower level of
plasma corticosterone at day 21 whereas LEW exhibited
a higher level at this time point. The fact that LEW rats
were less pain sensitive at day 4 after CCI induction in
spite of showing lower plasma glucocorticoid levels com-
pared to FIS and WIS rats may not seem consistent with
the expected protective anti-inflammatory effects of
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Figure 7 CCI-mediated mRNA expression of spinal EAATs in
LEW, FIS and WIS rats. The relative expression level of (A) the
neuronal (EAAT3) and (B) the glial glutamate transporter (EAAT2)
was determined in the spinal cord level L4/5 of Lewis (LEW), Fischer
(FIS) and Wistar (WIS) rats at days 4 and 21 after chronic constriction
injury of the right sciatic nerve. (A) EAAT3 mRNA was
downregulated in the LEW strain already after four days and still
after 21 days, in WIS only after 21 days, but was unchanged in FIS.
(B) EAAT2 mRNA expression was also decreased in LEW rats at d4
and d21. In WIS it was first downregulated but increased after
21 days and in the FIS strain the glial glutamate transporter was
nearly unchanged early after surgery but highly upregulated at the
later time point. The relative expression level indicates the fold
difference of the CCI group to the sham-operated control group
(control = 1). Data are expressed as mean ± s.e.m.
*p < 0.05, **p < 0.01.
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corticosterone may thus not be a major etiological factor
explaining the observed pain sensitivity discrepancies of
LEW rats compared to the other strains. Additional fac-
tors to be taken into consideration might be related to
strain-specific regulations of glutamatergic transmission
and/or of the glial cell activation in the spinal cord.
Glial cell activation
Microglial and astrocytic activation is involved in the ini-
tiation and maintenance of sensitivity in neuropathic or
pathological pain [27-29,36,53-56]. It has been demon-
strated that peripheral nerve injury leads to an activationof spinal microglia as characterized by morphological
modifications of these cells and by an enhanced expres-
sion of markers such as OX-42 and Iba-1 [34]. Our results
showed a time-dependent difference in the activation pat-
tern of microglia between LEW and FIS rats. In fact, 4 days
after CCI, Iba-1 mRNA expression was upregulated in
LEW rats whereas in FIS an upregulation was only seen
after 21 days. At the same time Iba-1 protein levels how-
ever tended to be upregulated in all strains. This effect
seemed to be somewhat more pronounced in LEW rats,
even though the observed alterations were not significant.
At a first glance, the data from day 21 seem to suggest a
major discrepancy between the enhanced relative ex-
pression of Iba-1 mRNA and the lack of a concomitant
elevation of the respective (immunohistochemically deter-
mined) protein level in the FIS rats (Figures 3A and 5).
Since the elevated mRNA expression could only be ob-
served in this late phase of neuropathy it is possible that
the translation into protein had not yet been significantly
implemented (at this time point of observation). Alterna-
tively, the described mismatch could have resulted from
unidentified regulatory mechanisms or from an activity-
dependent increase in the turnover of the protein as dis-
cussed by Mistry and colleagues [57] who described simi-
lar findings for TRPV1 mRNA and protein expression in
rat spinal ganglion neurons.
Since the different strains of rats did not display any differ-
ences in mechanical allodynia at this time point, we were not
able to establish any relation between Iba-1 expression and
pain sensitivity, contrary to the investigations of Romero-
Sandoval and colleagues [58-60] and other studies conclud-
ing that an inhibition of microglial activation reduces the de-
velopment of neuropathic pain [27,61-63]. In the present
conditions microglial activation was hence again not suffi-
cient to explain the observed differences in pain sensitivity.
On the other hand, the expression of the astrocytic
marker GFAP was not altered at day 4 after CCI. This is in
agreement with the assumption that microglia is the glial
cell type initially responding to nerve injury [37,64,65]. The
importance of astrocyte activation for the maintenance of
neuropathic pain is supported by studies from Romero-
Sandoval and colleagues [58,60]. Four days after L5 nerve
transection these investigators did not observe any robust
change of GFAP expression at the protein level. Neverthe-
less, it has been recently shown that neuropathic pain in-
duces an upregulation of GFAP expression in the spinal
cord from day 3 or day 4 after spinal nerve ligation or L5
spinal nerve transection [29,35]. Astrocytic activation per-
sists throughout the duration of neuropathic pain while
microglial activation may have declined again [66]. Al-
though LEW tended to express less GFAP than FIS rats, we
failed to demonstrate any significant upregulation or differ-
ence in GFAP expression between the two strains at day 21,
either at the transcript or at the protein levels. A CCI-
Le Coz et al. BMC Neuroscience 2014, 15:35 Page 10 of 13
http://www.biomedcentral.com/1471-2202/15/35related activation of astrocytes has however been demon-
strated by Garrison and colleagues [30].
As already discussed, astrocytes seem to be responsible
for the maintenance of hypersensitivity following peri-
pheral nerve injury [27,53,67] whereas microglia rather
seem to be involved in the induction of neuropathic pain
[34,68]. Additional mechanisms of pain regulation may
however have to be considered. Recent studies have e.g.
described the involvement of perivascular microglia in
inflammation and peripheral nerve injury. These antigen-
presenting cells reside in close association with astrocytes
and endothelial cells and express ED2 (ED2/CD163 sca-
venger receptor cysteine-rich group B family member)
[69], a molecule associated with anti-inflammatory pro-
cesses [70,71]. It has been shown that a L5 spinal nerve
transection reduces ED2 expression, whereas a canna-
binoid receptor 2 agonist enhances spinal ED2 expression
and inhibits tactile allodynia [59]. These findings suggest
that ED2 expressing perivascular microglia may have a
role in the processing of neuropathic pain. This subtype of
microglia could thus be differentially involved in the set-
ting of mechanical allodynia/hyperalgesia in LEW and FIS
rats, a factor that could contribute to the explanation of
the discrepancies in the respective pain thresholds.
Concerning our immunohistochemical assessment of
Iba-1 and GFAP protein expression, one point needs fur-
ther discussion. The fact that we used the side contrala-
teral to the CCI as control seems to imply that we did not
consider the potential development of mirror-image
neuropathic pain resulting from the activation of glia cells
[28]. Bilateral labeling of activated microglia in the spinal
cord dorsal horn following a unilateral spared nerve injury
has e.g. been described in rats [72]. In the present study,
the three tested strains also displayed contralateral albeit
less pronounced Iba-1 and GFAP immunoreactivity as
compared to the treated side. These lower levels of protein
expression are not necessarily accompanied by an increase
in pain sensitivity. In all animal groups we did in fact ob-
serve stable behavioral responses to contralateral paw
stimulation. This lack of alterations may be related to a
time dependent dissociation between pain behavior and
the measured biochemical parameters (see [73]). It is also
possible that a significantly more pronounced ipsilateral
expression of spinal mediators developed in the initial
phase preceding day 4 after CCI and then gradually de-
cayed, tending to converge with the respective values of
the untreated side. Taken together, the constancy of re-
sponses to stimulation of the non-treated side allowed us
to consider this side as a reference for the elucidation of
CCI-mediated effects.
Glutamate transporters
It is well known that the major part of glutamate re-
leased in the synaptic cleft is removed by surroundingastrocytes. The EAATs are located in the plasma mem-
brane of these cells and maintain the extracellular glu-
tamate concentration in the physiological range. EAATs
are known to play a critical role in both induction and
maintenance of neuropathic pain induced by peripheral
nerve injury [24,74]. In this framework, glucocorticoids
(GCs) as well as their receptors have also been shown to
be implicated. After peripheral nerve injury, Wang and
colleagues [26] have demonstrated a negative regulation
of EAAT3 through activated spinal GC receptors and a
concomitant positive regulation of the NMDA receptors,
highlighting the synergetic role of these two systems in
the enhancement of pain. In our study, EAAT2 and 3
were only downregulated 4 days post-surgery in the
spinal cord of LEW rats; no modification was observed
in FIS and in WIS rats. After 21 days, we could again
notice a decreased expression of glutamate transporters
in LEW, but also an increased expression of EAAT2
in FIS. This is inconsistent with previous studies de-
monstrating that CCI or inflammation causes a rapid
transient upregulation of EAATs in the spinal cord,
followed by a downregulation [24]. It should however be
kept in mind that we only studied transcript expression
levels of EAATs and that post-transcriptional regulation
could have led to different protein levels of the gluta-
mate transporters.
Taken together, the results we obtained with spinal
markers are conflicting: 21 days after CCI, we observed
an upregulation of Iba-1 mRNA in FIS rats, which
should be accompanied by pain hypersensitivity. Con-
comitantly, we demonstrated an upregulation of EAAT2,
which normally triggers a reduction of the sensitivity
[24]. These opposing processes might have counterba-
lanced each other, leading to a relative reduction of pain
sensitivity in FIS rats. In LEW rats, the documented
modifications of Iba-1 and EAATs should have led to
mechanical hyperalgesia [21,58,60,75]. We noticed the
contrary since LEW turned out to be the least sensitive
to pain. This points again to the fact that under the con-
ditions of the present study glial markers may not con-
stitute reliable indicators of pain sensitivity.
One final issue should be discussed with respect to
selecting day 21 as the only time point for the measure-
ment of biochemical parameters in the later phase of
neuropathy. The lack of differences in CCI-related me-
chanical allodynia between the strains at that time point
suggests that additional measurements at shorter inter-
vals might have been required to follow the temporal
relations between pain behavior and the expression of
biochemical markers in a more consistent way.
Conclusion
The complex network of pathways required for the
development and the maintenance of neuropathic pain
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markers or glutamate transporters expression, which
were insufficient to explain the differences in pain pro-
cessing between LEW, FIS and WIS rat strains. In this
context, it should be kept in mind that although the
differential HPA axis reactivity of LEW and FIS rats pro-
vides a widely accepted comparative model for inves-
tigating interactions between nervous, endocrine and
immune systems [10], these inbred strains also display
significant differences in gene expression [76] as well
as in cardiovascular and behavioral reactivity to stress
[77,78] that may impede the interpretation of our fin-
dings. Pharmacological studies based on manipulation of
the HPA axis (glucocorticoid receptor agonists and an-
tagonists, different doses and time courses) in a com-
mon rat strain will be required to gain further insight
into its potential implication in neuropathic pain. Finally,
it will be necessary to consider that supraspinal e.g. lim-
bic and descending pain control networks may play a
critical role [18,79,80].
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